<sentence id="0">Discussion</sentence>
<sentence id="1">IL-17 was first described as a T cell product with proinflammatory properties [ 5,22 ] .</sentence>
<sentence id="2">RA is characterized by hyperplasia of synovial lining cells and an intense infiltration by mononuclear cells [ 23 ] .</sentence>
<sentence id="3">Proinflammatory cytokines such as IL-1 and TNF-alpha are abundant in rheumatoid synovium , whereas the T cell-derived cytokines , especially IL-4 and interferon-gamma , have often proved difficult to detect in RA synovium [ 24 ] .</sentence>
<sentence id="4">Although T cells <scope type="spec" id="1"> <cue type="spec" id="1">may</cue> have a role in the augmentation of rheumatoid synovial inflammation</scope> , the <scope type="neg" id="0"><cue type="neg" id="0">lack</cue> of T cell-derived cytokines</scope> has limited its importance .</sentence>
<sentence id="5">In this respect , IL-17 is appealing because it has been described as a T cell-derived cytokine with proinflammatory properties .</sentence>
<sentence id="6">In our studies , we tried to evaluate how IL-17 production is regulated in RA PBMC , and which signaling pathway it used .</sentence>
<sentence id="7">Levels of IL-17 were found to be higher in RA synovial fluid than in OA synovial fluid [ 15 ] .</sentence>
<sentence id="8">However , there are few data available on the agents that stimulate IL-17 production in RA , although <scope type="spec" id="2"> the highest level of IL-17 production <cue type="spec" id="2">can</cue> be achieved by anti-CD3/anti-CD28 stimulation in healthy individuals [ 25 ]</scope> .</sentence>
<sentence id="9">In our experiments , PHA as mitogens , as well as anti-CD3/anti-CD28 for signaling through the T cell receptor , increased IL-17 production from RA PBMC in a dose-dependent manner .</sentence>
<sentence id="10">We found , by a cell proliferation assay <scope type="neg" id="3">( data <cue type="neg" id="3">not</cue> shown )</scope> , that this upregulation of IL-17 <scope type="spec" id="5"> <cue type="spec" id="5">might</cue> be due to increased cellular activity <scope type="neg" id="4"><cue type="neg" id="4">rather than</cue> to cellular proliferation</scope></scope> .</sentence>
<sentence id="11">IL-17 is produced mainly by activated CD4+ T cells , especially for Th1/Th0 cells , <scope type="neg" id="6"><cue type="neg" id="6">not</cue> the Th2 phenotype</scope> [ 26 ] .</sentence>
<sentence id="12">However , it can also be produced by CD8+ T cells via an IL-23 triggering mechanism in Gram-negative pulmonary infection [ 14 ] .</sentence>
<sentence id="13">In addition , IL-17 production was significantly augmented by T cells recognizing type II collagen in a collagen-induced arthritis model [ 27 ] .</sentence>
<sentence id="14">A complex interaction between cells in inflamed RA joints <scope type="spec" id="7"> <cue type="spec" id="7">might</cue> produce a variety of proinflammatory cytokines and chemokines</scope> , which also activate other cells in the joints .</sentence>
<sentence id="15">For example , IL-17 stimulates rheumatoid synoviocytes to secrete several cytokines such as IL-6 , IL-8 and tumor necrosis factor-stimulated gene 6 as well as prostaglandin E2 in vitro [ 12,28,29 ] .</sentence>
<sentence id="16">There are as yet few data available on the agents that stimulate IL-17 production in RA , although some cytokines ( IL-15 and IL-23 ) have been known to regulate IL-17 production [ 13,14 ] .</sentence>
<sentence id="17">We therefore investigated the in vitro production of IL-17 in RA PBMC responding to a variety of cytokines/chemokines and mitogens as well as T cell receptor ( TCR ) ligation using anti-CD3/anti-CD28 .</sentence>
<sentence id="18">Our studies demonstrated that IL-15 and MCP-1 as well as TCR ligation significantly increased the production of IL-17 in RA PBMC .</sentence>
<sentence id="19">Adding IL-15 or MCP-1 to TCR ligation augmented IL-17 production more markedly .</sentence>
<sentence id="20">In contrast , IL-1 and TNF-alpha , which are known to have proinflammatory properties and to be increased in RA joints , did <scope type="neg" id="8"><cue type="neg" id="8">not</cue> affect IL-17 production</scope> .</sentence>
<sentence id="21">Our data were consistent with a recent report that IL-15 triggered in vitro IL-17 production in PBMC , but TNF-alpha did <scope type="neg" id="9"><cue type="neg" id="9">not</cue> do so</scope> [ 13 ] .</sentence>
<sentence id="22">Although there were <scope type="neg" id="10"><cue type="neg" id="10">no</cue> data</scope> that MCP-1 directly induces T cell activation , it <scope type="spec" id="11"> <cue type="spec" id="11">might</cue> exert effects indirectly on T cells through the activation of monocytes/macrophages in PBMC cultures</scope> .</sentence>
<sentence id="23">As reported for normal individuals [ 25 ] , T cell activation through anti-CD3/anti-CD28 also increases IL-17 induction in RA PBMC .</sentence>
<sentence id="24">Although the signaling pathway for the induction of cytokines/chemokines by IL-17 has been documented widely [ 8,30,31 ] , <scope type="neg" id="12"><cue type="neg" id="12">no</cue> data have been available on how IL-17 production can be regulated by certain signaling pathways</scope> .</sentence>
<sentence id="25">By using signal transduction inhibitors , we therefore examined which signaling pathway was mainly involved in the induction of IL-17 in RA PBMC .</sentence>
<sentence id="26">We identified that anti-CD3-induced IL-17 production in RA PBMC was significantly hampered by the PI3K inhibitor LY294002 and the NF-kappaB inhibitor PDTC to comparable levels of basal production <scope type="neg" id="13"><cue type="neg" id="13">without</cue> stimulation</scope> .</sentence>
<sentence id="27">We also found that anti-CD3-induced IL-17 production was downregulated by the addition of SB203580 , a p38 MAPK inhibitor .</sentence>
<sentence id="28">It is interesting that a series of evidence supports crosstalk between NF-kappaB and p38 .</sentence>
<sentence id="29">In myocytes , IkappaB kinase-beta is activated by p38 [ 32 ] , and the activated p38 can stimulate NF-kappaB by a mechanism involving histone acetylase p300/CREB-binding protein [ 33 ] .</sentence>
<sentence id="30">Our results revealed that <scope type="neg" id="14">p38 MAPK activation was <cue type="neg" id="14">not</cue> affected by LY294002</scope> , whereas NF-kappaB binding activity was decreased by LY294002 , which provided the evidence for a p38 MAPK pathway independent of PI3K activation .</sentence>
<sentence id="31">The direct relationship between p38 and NF-kappaB for IL-17 production needs to be studied in future experiments .</sentence>
<sentence id="32"><scope type="spec" id="15"> The search for a downstream pathway of PI3K <cue type="spec" id="15">seemed</cue> to have a maximal response of Akt activation at 1 hour and a gradual loss of activity at 2 hours</scope> .</sentence>
<sentence id="33">The fact that Akt is phosphorylated upon anti-CD3 stimulation <scope type="spec" id="16"> <cue type="spec" id="16">suggests</cue> the <scope type="spec" id="17"> <cue type="spec" id="17">possible</cue> involvement of PI3K in the induction of IL-17 in RA</scope></scope> .</sentence>
<sentence id="34">In view of the fact that NF-kappaB was also activated by anti-CD3/anti-CD28 , IL-15 or mitogens in our experiments , it is most <scope type="spec" id="18"> <cue type="spec" id="18">likely</cue> that the NF-kappaB pathway is also actively involved in the induction of IL-17 in RA PBMC</scope> .</sentence>
<sentence id="35">In contrast , <scope type="neg" id="19">the AP-1 signal transduction pathway , another important signaling pathway for cytokines/chemokines , was <cue type="neg" id="19">not</cue> activated in our experiments <scope type="neg" id="20">( data <cue type="neg" id="20">not</cue> shown )</scope></scope> .</sentence>
<sentence id="36">Although PI3K and its downstream kinase Akt in association with NF-kappaB have been reported to deliver activating signals in many cell types , the data on the signal inducing IL-17 are <scope type="neg" id="21"><cue type="neg" id="21">lacking</cue></scope> .</sentence>
<sentence id="37">Our data clearly demonstrated that PI3K/Akt and resultant NF-kappaB activation <scope type="spec" id="22"> <cue type="spec" id="22">could</cue> be an important arbitrator of the upregulation of IL-17 in RA , on the basis of our experiments showing simultaneous blocking of NF-kappaB binding activity in the IL-17 promoter by PDTC and LY294002</scope> .</sentence>
<sentence id="38">Considering its proinflammatory activities and successful induction of anti-IL-17 for ameliorating arthritis in animal models [ 2,6,34-36 ] , understanding the IL-17 signaling pathway is an important element of developing new targeted therapies in RA .</sentence>